Immuneering Corp
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
IMRX$3.65-0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
EXHIBIT INDEX
| Incorporated by Reference · Filed/FurnishedHerewith | ||||||
|---|---|---|---|---|---|---|
| Exhibit Number · Exhibit Description · Form · File No. · Exhibit · FilingDate | ||||||
| 3.1 | Amended and Restated Certificate of Incorporation of Immuneering Corporation | 10-Q | 001-40675 | 3.1 | 9/9/2021 | |
| 3.2 | Amended and Restated Bylaws of Immuneering Corporation | 8-K | 001-40675 | 3.1 | 2/2/2024 | |
| 4.1 | Form of Pre-Funded Warrant | 8-K | 001-40675 | 4.1 | 8/25/2025 | |
| 4.2 | Form of Purchase Warrant | 8-K | 001-40675 | 4.2 | 8/25/2025 | |
| 10.1# | Immuneering Corporation Non-Employee Director Compensation Program, as amended, effective August 12, 2025 | * | ||||
| 10.2 | Equity Distribution Agreement, dated as of August 13, 2025, by and between Immuneering Corporation and Piper Sandler & Co. | S-3 | 333-289589 | 1.2 | 8/13/2025 | |
| 10.3## | Form of Securities Purchase Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the investors party thereto | 8-K | 001-40675 | 10.1 | 8/25/2025 | |
| 10.4 | Form of Registration Rights Agreement, dated as of August 21, 2025, by and among Immuneering Corporation and the investors party thereto | 8-K | 001-40675 | 10.2 | 8/25/2025 | |
| 10.5## | Securities Purchase Agreement, dated as of September 24, 2025, by and between Immuneering Corporation and Aventis Inc. | 8-K | 001-40675 | 10.1 | 9/24/2025 | |
| 31.1 | Certification of Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a). | * | ||||
| 31.2 | Certification of Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a). | * | ||||
| 32.1 | Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350. | ** | ||||
| 32.2 | Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350. | ** | ||||
| Incorporated by Reference | Filed/FurnishedHerewith | |||||
| Exhibit Number | Exhibit Description | Form | File No. | Exhibit | FilingDate | |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | * | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | * | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | * | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | * | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | * | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.